Cetuximab with hepatic arterial infusion of chemotherapy for the treatment of colorectal cancer liver metastases

Anticancer Research

Volumn 28, Issue 4 C, 2008, Pages 2459-2467

  Neyns, Bart ^a,b   Aerts, Maridi ^a   Van Nieuwenhove, Yves ^b   Fontaine, Christel ^a   De Coster, Lore ^a   Schallier, Dennis ^a   Vanderauwera, Jacques ^a   De Munck, Floris ^b   Vandenbroucke, Frederik ^b   Everaert, Hendrik ^b   Meert, Vanessa ^b   De Mey, Johan ^b   De Ridder, Mark ^b   Delvaux, Georges ^b   De Grève, Jacques ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

5 Fluorouracil; Arterial; Cetuximab; Colorectal; Infusion; Irinotecan; Metastases; Oxaliplatin

Indexed keywords

ANTIBIOTIC AGENT; BUPRENORPHINE; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; ELVORIN; FLUCLOXACILLIN; FLUOROURACIL; FOLIC ACID; IRINOTECAN; MINOCYCLINE; OCTREOTIDE; OXALIPLATIN; PROTON PUMP INHIBITOR; TRAMADOL;

ABDOMINAL PAIN; ACNE; ADD ON THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILE DUCT DILATATION; BILE DUCT FISTULA; BILIRUBIN BLOOD LEVEL; CANCER GROWTH; CANCER STAGING; CATHETER COMPLICATION; CATHETER MIGRATION; CLINICAL ARTICLE; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG SAFETY; DRY SKIN; DUODENUM ULCER; FEBRILE NEUTROPENIA; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; INTERSTITIAL PNEUMONIA; INTESTINAL BLEEDING; INTESTINE INFECTION; INTESTINE PNEUMONITIS; LEUKOPENIA; LIVER CIRCULATION; LIVER METASTASIS; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; POLYNEUROPATHY; PRIORITY JOURNAL; SEPTICEMIA; SIDE EFFECT; SKIN EXFOLIATION; SKIN FISSURE; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT FAILURE; UPPER GASTROINTESTINAL BLEEDING;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS;

EID: 48849087988     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Boyle P and Ferlay J: Mortality and survival in breast and colorectal cancer. Nat Clin Pract Oncol 2: 424-425, 2005.
2. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F, Ghemard O, Levi F and Bismuth H: Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240: 644-657; discussion 657-648, 2004.
3. Douillard Jy, Cunningham D, Roth Ad, Navarro M, James Rd, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L and Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041-1047, 2000.
4. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C and De Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229-237, 2004.
5. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crino L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M and Masi G: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25: 1670-1676, 2007.
6. Rothenberg MI, Oza Am, Bigelow Rh, Berlin Jd, Marshall JI, Ramanathan Rk, Hart LI, Gupta S, Garay Ca, Burger Bg, Le Bail N and Haller Dg: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21: 2059-2069, 2003.
7. Hurwitz Hi, Fehrenbacher L, Hainsworth Jd, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny Wf and Kabbinavar F: Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23: 3502-3508, 2005.
8. Saltz Lb, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang Ts, Rivera F, Couture F, Sirzen F and Cassidy J: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26: 2013-2019, 2008.
9. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA and Benson AB, 3rd: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25: 1539-1544, 2007.
10. Folprecht G, Grothey A, Alberts S, Raab H and Kohne C: Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16: 1311-1319, 2005.
11. Mendelsohn J and Baselga J: Epidermal growth factor receptor targeting in cancer. Semin Oncol 33: 369-385, 2006.
12. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I and Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345, 2004.
13. Guthoff I, Lotspeich E, Fester C, Wallin I, Schatz M, Ehrsson H and Kornmann M: Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility. Anticancer Res 23: 5203-5208, 2003.
14. Jonker D, O'Callaghan C, Karapetis Cs, Zalcberg J, Tu D, Au H, Berry S, Krahn M, Price T, Simes R, Tebbutt N, Van Hazel G, Wierzbicki R, Langer C and Moore M: Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: 2040-2048, 2007.
15. Van Cutsem E, Nowacki M, Lang I, Cascinu S, Shchepotin I, Maurel J, Rougier P, Cunningham D, Nippgen J and Kohne C: Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. ASCO Meeting Abstracts 25: 4000, 2007.
16. Bokemeyer C, Bondarenko I, Makhson A, Hartmann J, Aparicio J, Zampino M, Donea S, Ludwig H, Zubel A and Koralewski P: Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. ASCO Meeting Abstracts 25: 4035, 2007.
17. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon J, Van Laethem J, Maurel J, Richardson G, Wolf M and Amado R: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658-1664, 2007.
18. Van Cutsem E, Siena S, Humblet Y, Canon J, Maurel J, Bajetta E, Neyns B, Kotasek D, Santoro A, Scheithauer W, Spadafora S, Amado R, Hogan N and Peeters M: An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 19: 92-98, 2008.
19. Cohen A and Kemeny N: An update on hepatic arterial infusion chemotherapy for colorectal cancer. Oncologist 8: 553-566, 2003.
20. Zorzi D, Laurent A, Pawlik T, Lauwers G, Vauthey J and Abdalla E: Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 94: 274-286, 2007.
21. Mocellin S, Pilati P, Lise M and Nitti D: Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol 25: 5649-5654, 2007.
22. Kerr D, Ledermann J, Mcardle C, Buckels J, Neoptolemos J, Seymour M, Doughty J, Budden J and Taylor I: Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil. J Clin Oncol 13: 2968-2972, 1995.
23. Kerr D, Mcardle C, Ledermann J, Taylor I, Sherlock D, Schlag PM, Buckels J, Mayer D, Cain D and Stephens R: Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet 361: 368-373, 2003.
24. Lorenz M and Muller H: Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 18: 243-254, 2000.
25. Carnaghi C, Santoro A, Rimassa L, Doci R, Rosati R, Pedicini V, Gullo G, Zuradelli M, Abbadessa G, Morenghi E, Marcon I and Garassino I: The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and ultra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: a phase II study. Invest New Drugs 25: 479-485, 2007.
26. Kern W, Beckert B, Lang N, Stemmler J, Beykirch M, Stein J, Goecke E, Waggershauser T, Braess J, Schalhorn A and Hiddemann W: Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. Ann Oncol 12: 599-603, 2001.
27. Kern W, Beckert B, Lang N, Waggershauser T, Braess J, Schalhorn A and Hiddemann W: Hepatic arterial infusion with oxaliplatin, folinic acid, and 5-fluorouracil in patients with hepatic metastases from colorectal cancer: role of carcino-embryonic antigen in assessment of response. Anticancer Res 20: 4973-4975, 2000.
28. Mancuso A, Giuliani R, Accettura C, Palma M, D'auria G, Cecere F, Paoluzzi L, Bezzi M, Massidda B and Cortesi E: Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer. Anticancer Res 23: 1917-1922, 2003.
29. Neyns B, Van Nieuwenhove Y, Aerts M, Fontaine C, Vermeij J, Schallier D, Decoster L, De Mey J, Vandenbroucke F, Hoorens A, Delvaux G and De Greve J: Hepatic arterial infusion of oxaliplatin and L-folinic acid-modulated 5-fluorouracil for colorectal cancer liver metastases. Anticancer Res 26: 611-619, 2006.
30. Ducreux M, Ychou M, Laplanche A, Gamelin E, Lasser P, Husseini F, Quenet F, Viret F, Jacob J, Boige V, Elias D, Delperro J and Luboinski M: Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 23: 4881-4887, 2005.
31. Kemeny N, Jarnagin W, Paty P, Gonen M, Schwarte L, Morse M, Leonard G, D'angelica M, Dematteo R, Blumgart L and Fong Y: Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 23: 4888-4896, 2005.
32. Boige V, Malka D, Elias D, Castaing M, De Baere T, Goere D, Dromain C, Pocard M and Ducreux M: Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol 15: 219-226, 2008.
33. Gallagher D, Capanu M, Raggio G and Kemeny N: Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis. Ann Oncol 18: 1995-1999, 2007.
34. Van Nieuwenhove Y, Aerts M, Neyns B and Delvaux G: Techniques for the placement of hepatic artery catheters for regional chemotherapy in unresectable liver metastases. Eur J Surg Oncol 33: 336-340, 2007.
35. Hildebrandt B, Pech M, Nicolaou A, Langrehr J, Kurcz J, Bartels B, Miersch A, Felix R, Neuhaus P, Riess H, Dorken B and Ricke J: Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with colorectal liver metastases: a Phase II-study and historical comparison with the surgical approach. BMC Cancer 7: 69, 2007.
36. Therasse P, Arbuck Smeetingg, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom A, Christian M and Gwyther S: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
37. Benoist S, Brouquet A, Penna C, Julie C, El Hajjam M, Chagnon S, Mitry E, Rougier P and Nordlinger B: Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 24: 3939-3945, 2006.
38. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E and Tejpar S: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19: 508-515, 2008.
39. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Bue E, Ychou M, Bouche O, Landi B, Louvet C, Andre T, Bibeau F, Diebold M, Rougier P, Ducreux M, Tomasic G, Emile J, Penault-Llorca F and Laurent-Puig P: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26: 374-379, 2008.
40. Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, Etienne L, Cavalli F and Mazzucchelli L: PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97: 1139-1145, 2007.
41. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Calais M, Bastit L, Killian A, Sesboue R, Tuech J, Queuniet A, Paillot B, Sabourin J, Michot F, Michel P and Frebourg T: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 96: 1166-1169, 2007.
42. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S and Bardelli A: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6: 279-286, 2005.